NYSE •
Healthcare •
Biotechnology •
Quote as of 09/03/2026 14:09
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization1,450.39 mln
Float33.50 mln
Earnings Date03/24/2027
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
38.38
Modest upside
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.11
Very low leverage
ROE
-49.63
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Alto Neuroscience is a drug development company based in Mountain View, California, focused on creating new treatments for brain and mental health conditions. The company has several medications in various stages of clinical testing, targeting conditions such as bipolar depression, major depressive disorder, schizophrenia-related cognitive impairment, and Parkinson's disease. Founded in 2019, Alto Neuroscience is working to advance these experimental drugs through clinical trials toward potential approval and patient use.
